Citius Pharmaceuticals (NASDAQ:CTXR) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research note released on Wednesday,Benzinga reports. They currently have a $6.00 target price on the stock.

CTXR has been the topic of a number of other research reports. Citigroup lowered shares of Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 23rd. Maxim Group lowered shares of Citius Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd.

Citius Pharmaceuticals Stock Down 1.5%

Shares of CTXR stock opened at $1.28 on Wednesday. Citius Pharmaceuticals has a fifty-two week low of $0.65 and a fifty-two week high of $17.00. The firm’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.41.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.04). The firm had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million. Analysts expect that Citius Pharmaceuticals will post -4.5 EPS for the current year.

Institutional Trading of Citius Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals in the second quarter worth $32,000. Arkadios Wealth Advisors increased its stake in shares of Citius Pharmaceuticals by 100.0% in the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock worth $32,000 after buying an additional 10,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Citius Pharmaceuticals by 103.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after buying an additional 4,168 shares during the last quarter. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.